Adicet Bio (ACET) Operating Leases (2020 - 2026)

Adicet Bio's Operating Leases history runs 7 years deep, the most recent figure standing at $10.2 million for Q1 2026.

• In Q1 2026, Operating Leases fell 23.38% year-over-year to $10.2 million; the TTM figure through Mar 2026 stood at $10.2 million (down 23.38% YoY), while the FY2025 annual figure was $10.9 million, down 22.64% from the prior year.
• Operating Leases for Q1 2026 stood at $10.2 million, down from $10.9 million in the prior quarter.
• The five-year high for Operating Leases was $20.5 million in Q1 2023, with the low at $10.2 million in Q1 2026.
• The 5-year median for Operating Leases is $17.7 million (2023), against an average of $16.6 million.
• The sharpest annual moves came in 2023 and 2025: Operating Leases advanced 9.0% in 2023, then sank 33.81% in 2025.
• Adicet Bio's Operating Leases stood at $18.5 million in 2022, then slipped by 4.47% to $17.7 million in 2023, then fell by 20.34% to $14.1 million in 2024, then fell by 22.64% to $10.9 million in 2025, then slipped by 6.87% to $10.2 million in 2026.
• Business Quant data shows ACET's Operating Leases at $10.2 million in Q1 2026, $10.9 million in Q4 2025, and $14.6 million in Q3 2025.